ReNeuron Group plc, Annual General Meeting, Sep 17, 2009, at 10:00 GMT Time. Location: Morrison & Foerster, City Point, One Ropemaker Street, London, EC2Y 9AW, United Kingdom. Agenda: To consider trading update.

ReNeuron Group plc filed its Annual on July 31, 2009 for the period ending March 31, 2009. In this report its auditor, PricewaterhouseCoopers LLP, gave an unqualified opinion expressing doubt that the company can continue as a going concern.

ReNeuron Group plc announced that the UK Gene Therapy Advisory Committee (GTAC) has issued a Favourable Opinion subject to conditions in respect of ReNeuron's proposed Phase I clinical trial with its ReN001 stem cell therapy for stroke. This development follows on from the earlier Provisional Opinion given by GTAC in May and is the result of further interactions between the Principal Investigator for the trial, ReNeuron and GTAC over the intervening period. GTAC acts as the national research ethics committee for gene therapy and stem cell therapy clinical trials in the UK. The conditions to the Favourable Opinion relate to clinical trial protocol amendments and the provision of supplemental, non-safety-related pre-clinical data. The company will now work with GTAC to both clarify and address the Favourable Opinion conditions as soon as possible, prior to commencing the clinical trial.